Chromone derivatives

Claim 2

A chromone derivative having the general formula: ##STR43## in which one of the radicals R and R' is in the 2 position on the chromone ring and the other of the radicals R and R' is in the 3 position, R' is a hydrogen atom or a lower alkyl radical, and R is the group: ##STR44## in which both R 1 and R 2 are a hydrogen atom or a lower alkyl radical, n is an integer of from 1 to 5, R 3 and R 4 are identical or different and comprise a hydrogen atom or a lower cycloalkyl radical or a hydroxy substituted lower cycloalkyl or alkyl radical, or form with the nitrogen atom a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, morpholine and N-hydroxy ethyl piperazine.

Claim 3

The derivative of claim 1, wherein R' is a hydrogen atom when in the 2 position.

Claim 4

The derivative of claim 1, wherein R' is a lower alkyl radical when in the 3 position.

Claim 5

The derivative of claim 3, wherein R' is a methyl radical.

Claim 6

The derivative of claim 1, wherein R 1 is the same as R 2 and is a hydrogen atom or a methyl group and wherein n is 2, 3, 4 or 5.

Claim 7

The derivative of claim 1, wherein R 3 and R 4 are an ethyl, n-butyl or 2-hydroxy propyl group.

Claim 8

The derivative of claim 1, wherein R 3 is a hydrogen atom and R 4 is an isopropyl or terbutyl group.

Claim 9

The derivative of claim 1, wherein R 3 is a cyclohexyl group and R 4 is a methyl or isopropyl group.

Claim 10

The derivative of claim 1, wherein R 3 and R 4 combine with the nitrogen atom to form a heterocyclic ring selected from the group consisting of pyrrolidine, piperidine, morpholine and N-hydroxy ethyl piperazine.

Claim 11

The derivative of claim 1, which is in the form of a salt of addition of a pharmaceutically acceptable acid.

Claim 12

The derivative of claim 1, wherein R is in the 2 position on the chromone ring.

Claim 13

The derivative of claim 1, which is selected from the group consisting of 2-[4-(3N,N-dibutylamino propoxy)3,5-dimethyl benzoyl] chromone hydrochloride, 3-[4-(3-N,N-dibutylamino propoxy)3,5-dimethyl benzoyl] chromone hydrochloride, 2-[2-(3-N,N-dibutylamino propoxy) benzoyl] chromone hydrochloride, 2-[4-(2-N,N-diethylamino ethoxy) benzoyl] chromone hydrochloride, 2[4-(3-N,N-dibutylamino propoxy) benzoyl] chromone hydrochloride, 2-[4-(3-N,N-dibutylamino propoxy) 3,5-dimethyl benzoyl] 3-methyl chromone hydrochloride, 2-[4-(2-N,N-dibutylamino ethoxy) 3,5-dimethyl benzoyl] chromone hydrochloride, 2-[4-(3-N-isopropylamino propoxy) 3,5-dimethyl benzoyl] chromone hydrochloride, 2-[4-(3-N, terbutylamino propoxy) 3,5-dimethyl benzoyl] chromone hydrochloride 2[4-(N, cylcohexyl 3-N-isopropylamino propoxy) 3,5- dimethyl benzoyl]chromone hydrochloride, 2-[4-(3-N-morpholino propoxy) 3,5-dimethyl benzoyl] chromone iodomethylate, 2-[4-(N-hydroxyethyl 3-piperazino) 3,5-dimethyl benzoyl] chromone hydrochloride 2-[4-(3-N,N-diiasopropanolamino propoxy) 3,5-dimethyl benzoyl] chromone hydrochloride, 2-[4-(3-N-piperidino propoxy) 3,5-dimethyl benzoyl] chromone iodomethylate, 2-[4-(N-methyl 3-N-cyclohexoamino propoxy) 3,5-dimethyl benzoyl] chromone iodomethylate, 2-[4-(4-N,N-dibutylamino butoxy) 3,5-dimethyl benzoyl] chromone iodomethylate, 2-[4-(5-N, N-dibutylamino pentoxy) 3,5-dimethyl benzoyl] chromone iodomethylate, and 2-[4-(3-N-pyrrolidino propoxy) 3,5-dimethyl benzoyl] chromone iodomethylate.

Claim 14

A pharmaceutical composition useful in treating arrhythmia, bradycardia, tachycardia, and heart disorders necessitating sympathico inhibition comprising an effective amount of a derivative of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 15

The pharmaceutical composition of claim 13, which is in a tablet or pill form containing from 50 to 300 mg.

Claim 16

The pharmaceutical composition of claim 14 which is in tablet or pill form containing 100 or 200 mg.

Claim 17

A method of treating arrhythmia, bradycardia, tachycardia, and heart disorders necessitating sympathico inhibition which comprises administering an effective amount of a non-toxic dosage of the pharmaceutical composition of claim 13.